MEREO BIOPHARMA GROUP PLC Increase Decrease Through Conversion Of Convertible Instruments
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase Decrease Through Conversion Of Convertible Instruments of GBP 54.87 million for the 12-month period ending 2020-12-31, per its 20-F filed 2021-03-31.
Discontinued › Notes
ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments · last filed 2021-11-02
| Period end | Increase Decrease Through Conversion Of Convertible Instruments 6 month | Increase Decrease Through Conversion Of Convertible Instruments 12 month | Increase Decrease Through Conversion Of Convertible Instruments 12 month as first filed |
|---|---|---|---|
| 2020-12-31 | 54.87M GBP 20-F · filed 2021-03-31 | ||
| 2020-06-30 | 54.87M GBP 6-K · filed 2021-11-02 | ||
| 2017-12-31 | 62.00K GBP 20-F · filed 2020-06-15 | 62.38K GBP 20-F/A · filed 2019-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |